Denosumab biosimilar(Biocon Biologics)(Denosumab biosimilar(Biocon Biologics)) - 在研适应症：骨质疏松症_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

BMAB1000、Bmab-1000

靶点-

作用机制-

治疗领域

内分泌与代谢疾病皮肤和肌肉骨骼疾病

在研适应症

骨质疏松症

非在研适应症-

原研机构

Biocon Biologics Ltd. (India)

在研机构

Biocon Biologics Ltd. (India)

Biocon Ltd.

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Denosumab biosimilar(Biocon Biologics) 相关的临床试验

NCT05345691 / Completed临床3期

A Randomized, Double-Blind, Multicenter, Parallel-Arm Phase 3 Study to Compare the Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis

This is a randomized, double-blind, multicenter, parallel-arm, Phase 3 study to compare the efficacy, PK (Pharmacokinetic), PD (Pharmacodynamic), safety, and immunogenicity of Bmab 1000 and Prolia® in postmenopausal women with osteoporosis

开始日期2022-05-24

申办/合作机构

Biocon Ltd.

NCT05323708 / Completed临床1期

A Randomized, Double-blind, Two-arm, Single-dose, Parallel-Group Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Bmab 1000 and Prolia® in Normal Healthy Volunteers

This study is to compare the Pharmacokinetics, Pharmacodynamics, safety, and tolerability of Bmab 1000 and Prolia® in normal healthy volunteers.

开始日期2022-03-09

申办/合作机构

Biotrial Research SAS

100 项与 Denosumab biosimilar(Biocon Biologics) 相关的临床结果

登录后查看更多信息

100 项与 Denosumab biosimilar(Biocon Biologics) 相关的转化医学

登录后查看更多信息

100 项与 Denosumab biosimilar(Biocon Biologics) 相关的专利（医药）

登录后查看更多信息

100 项与 Denosumab biosimilar(Biocon Biologics) 相关的药物交易

登录后查看更多信息